标题
TNF Blockade Maintains an IL-10+ Phenotype in Human Effector CD4+ and CD8+ T Cells
作者
关键词
-
出版物
Frontiers in Immunology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2017-02-15
DOI
10.3389/fimmu.2017.00157
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- IL-17+ CD8+ T cells: Differentiation, phenotype and role in inflammatory disease
- (2016) Ushani Srenathan et al. IMMUNOLOGY LETTERS
- Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF–TNF-RII binding in rheumatoid arthritis
- (2016) Dao Xuan Nguyen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CD8+ T cells in human autoimmune arthritis: the unusual suspects
- (2016) Alessandra Petrelli et al. Nature Reviews Rheumatology
- The Interplay Between Monocytes/Macrophages and CD4+ T Cell Subsets in Rheumatoid Arthritis
- (2015) Ceri A. Roberts et al. Frontiers in Immunology
- Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis
- (2014) Der-Yuan Chen et al. ANNALS OF THE RHEUMATIC DISEASES
- Th17 and regulatory T cell balance in autoimmune and inflammatory diseases
- (2014) Mélissa Noack et al. AUTOIMMUNITY REVIEWS
- Inhibition of TNF receptor signaling by anti-TNFα biologicals primes naïve CD4+ T cells towards IL-10+ T cells with a regulatory phenotype and function
- (2014) Martine A. Boks et al. CLINICAL IMMUNOLOGY
- TNF-α blockade induces IL-10 expression in human CD4+ T cells
- (2014) Hayley G. Evans et al. Nature Communications
- Interleukin-17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression
- (2014) Bina Menon et al. Arthritis & Rheumatology
- IL-4 induces a suppressive IL-10-producing CD8+ T cell population via a Cdkn2a-dependent mechanism
- (2013) Yapu Zhao et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Clonal Expansions of CD8+ T Cells with IL-10 Secreting Capacity Occur during Chronic Mycobacterium tuberculosis Infection
- (2013) Joshua C. Cyktor et al. PLoS One
- Biologics-induced autoimmune diseases
- (2012) Roberto Perez-Alvarez et al. CURRENT OPINION IN RHEUMATOLOGY
- Etanercept Downregulates the Th17 Pathway and Decreases the IL-17+/IL-10+ Cell Ratio in Patients with Psoriasis Vulgaris
- (2012) Emiliano Antiga et al. JOURNAL OF CLINICAL IMMUNOLOGY
- CD8+ T Cells in the Lesional Skin of Atopic Dermatitis and Psoriasis Patients Are an Important Source of IFN-γ, IL-13, IL-17, and IL-22
- (2012) DirkJan Hijnen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases
- (2011) Warren Strober et al. GASTROENTEROLOGY
- Highly Activated Cytotoxic CD8 T Cells Express Protective IL-10 at the Peak of Coronavirus-Induced Encephalitis
- (2011) K. Trandem et al. JOURNAL OF IMMUNOLOGY
- Number and phenotype of rheumatoid arthritis patients’ CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept
- (2011) Céline Blache et al. RHEUMATOLOGY
- T cells in multiple sclerosis and experimental autoimmune encephalomyelitis
- (2010) J. M. Fletcher et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- IL-27 induces the differentiation of Tr1-like cells from human naive CD4+ T cells via the phosphorylation of STAT1 and STAT3
- (2010) Hui Wang et al. IMMUNOLOGY LETTERS
- Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs
- (2010) Yenkel Grinberg-Bleyer et al. JOURNAL OF CLINICAL INVESTIGATION
- Critical Role for TNF in the Induction of Human Antigen-Specific Regulatory T Cells by Tolerogenic Dendritic Cells
- (2010) F. S. Kleijwegt et al. JOURNAL OF IMMUNOLOGY
- Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis
- (2010) Pieter C. M. Res et al. PLoS One
- Infliximab and the TNF-α system
- (2009) Ellen C. Ebert AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis
- (2009) H. M. Baldwin et al. ANNALS OF THE RHEUMATIC DISEASES
- Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
- (2009) Merete Lund Hetland et al. ARTHRITIS AND RHEUMATISM
- Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
- (2009) Zehra Kaymakcalan et al. CLINICAL IMMUNOLOGY
- Differences in binding and effector functions between classes of TNF antagonists
- (2009) Taruna Arora et al. CYTOKINE
- IL-27 Is a Key Regulator of IL-10 and IL-17 Production by Human CD4+ T Cells
- (2009) G. Murugaiyan et al. JOURNAL OF IMMUNOLOGY
- Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10
- (2009) Jie Sun et al. NATURE MEDICINE
- Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis
- (2009) Peter C. Taylor et al. Nature Reviews Rheumatology
- Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor and systemic immune activation
- (2008) N M Moutsopoulos et al. ANNALS OF THE RHEUMATIC DISEASES
- Mechanisms for cytotoxic effects of anti–tumor necrosis factor agents on transmembrane tumor necrosis factor α–expressing cells: Comparison among infliximab, etanercept, and adalimumab
- (2008) Hiroki Mitoma et al. ARTHRITIS AND RHEUMATISM
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
- (2007) Daniel Tracey et al. PHARMACOLOGY & THERAPEUTICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started